Intellia Therapeutics Finalizes Terms for $400M At-The-Market Offering
NTLA has more than doubled off its 52-week low of $5.9 on elevated volume (3.1× avg).
Summary
Intellia Therapeutics filed a prospectus supplement detailing the terms of its expanded $400 million At-The-Market (ATM) offering, enabling the company to sell common stock to fund operations and clinical development.
Key Events · Financing and Capital Events · NTLA
-
Formalizes $400M ATM Offering
Intellia Therapeutics filed a 424B5 prospectus supplement to finalize the terms of its expanded At-The-Market (ATM) equity offering, allowing the sale of up to $400 million in common stock.
-
Significant Potential Dilution
The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders.
-
Capital for Clinical Development
Proceeds from the offering are intended to fund research and clinical development of pipeline candidates, including the recently cleared MAGNITUDE Phase 3 trial, working capital, and general corporate purposes, extending the company's liquidity.
-
Follows Concurrent 8-K Announcement
This filing provides the detailed prospectus for the ATM program expansion, which was announced in a separate 8-K filing on the same date, March 2, 2026.
Analysis · NTLA · Life Sciences
This 424B5 prospectus supplement formalizes the terms of Intellia Therapeutics' expanded At-The-Market (ATM) equity offering, allowing the company to sell up to $400 million in common stock. This filing provides the detailed legal framework for the ATM program, which was announced in a separate 8-K filing on the same day, March 2, 2026. The offering, if fully utilized at an assumed price of $14.28 per share, could result in the issuance of approximately 28.01 million new shares, representing a potential dilution of about 24.08% to existing shareholders. While dilutive, this substantial capital raise is crucial for funding ongoing research and clinical development, including the recently cleared MAGNITUDE Phase 3 trial, and extends the company's liquidity runway. Investors should monitor the pace of ATM sales and their impact on share price.
At the time of this filing, NTLA was trading at $15.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $5.90 to $28.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.